The inhibition of platelet adhesion and activation on collagen during balloon angioplasty by collagen-binding peptidoglycans

Biomaterials

Volumn 32, Issue 10, 2011, Pages 2516-2523

  Paderi, John E ^a   Stuart, Kate ^a   Sturek, Michael ^b   Park, Kinam ^a   Panitch, Alyssa ^a  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Balloon Angioplasty; Biomimetic material; Collagen; Intimal hyperplasia; Peptide; Platelet; Thrombosis

Indexed keywords

BALLOON ANGIOPLASTY; BINDING PEPTIDE; BIOMIMETIC POLYMERS; BLOOD LOSS; DERMATAN SULFATE; HIGH AFFINITY; INFLAMMATORY CELLS; INFUSION CATHETER; INTIMAL HYPERPLASIA; PEPTIDOGLYCANS; PLATELET ACTIVATION; PLATELET ADHESION; PLATELET DEPOSITION; STENT DEPLOYMENTS; TARGET VESSELS; THROMBOSIS; THROMBUS FORMATION; VESSEL WALLS;

ADHESION; BALLOONS; BIOMIMETICS; BLOOD VESSELS; DISEASES; FUNCTIONAL POLYMERS; PEPTIDES; PLATELETS;

COLLAGEN;

BIOMIMETIC MATERIAL; COLLAGEN; DERMATAN SULFATE; PEPTIDOGLYCAN; POLITEF; POLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; BINDING AFFINITY; DRUG BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIPIG; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION;

ANGIOPLASTY, BALLOON; ANIMALS; BIOCOMPATIBLE MATERIALS; CAROTID ARTERIES; CELL MOVEMENT; DERMATAN SULFATE; DIFFUSION; ENDOTHELIAL CELLS; FIBRILLAR COLLAGENS; HORSES; HUMANS; PEPTIDES; PEPTIDOGLYCAN; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; RHEOLOGY; SWINE; SWINE, MINIATURE;

SUIDAE;

EID: 79251593784     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.12.025     Document Type: Article

References (44)

1. Steele P.M., Chesebro J.H., Stanson A.W., Holmes D.R., Dewanjee M.K., Badimon L., et al. Balloon angioplasty - natural history of the pathophysiological response to injury in a pig model. Circ Res 1985, 57(1):105-112.
2. Jennings L.K. Role of platelets in atherothrombosis. Am J Cardiol 2009, 103(3A):4A-10A.
3. Vanhoutte P.M., Houston D.S. Platelets, endothelium, and vasospasm. Circulation 1985, 72(4):728-734.
4. Drachman Douglas E., Simon D.I. Inflammation as a mechanism and therapeutic target for in-stent restenosis. Curr Atheroscler Rep 2005, 7:44-49.
5. Libby P., Schwartz D., Brogi E., Tanaka H., Clinton S.K. A cascade model for restenosis - a special case of atherosclerosis progression. Circulation 1992, 86(6):47-52.
6. Braunwald E., Angiolillo D., Bates E., Berger P.B., Bhatt D., Cannon C.P., et al. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol 2008, 31(3):I17-I20.
7. Di Mario Carlo F.G. Embolization: the " dark side" of percutaneous coronary interventions. JACC Cardiovasc Interv 2008, 1(3):277-278.
8. Welt F.G.P., Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002, 22(11):1769-1776.
9. Furie B., Furie B.C. Mechanisms of disease: mechanisms of thrombus formation. N Engl J Med 2008, 359(9):938-949.
10. Early M., Lally C., Prendergast P.J., Kelly D.J. Stresses in peripheral arteries following stent placement: a finite element analysis. Comput Methods Biomech Biomed Eng 2009, 12(1):25-33.
11. Schillinger M., Sabeti S., Loewe C., Dick P., Amighi J., Mlekusch W., et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006, 354(18):1879-1888.
12. Scheinert D., Scheinert S., Sax J., Piorkowski C., Braunlich S., Ulrich M., et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005, 45(2):312-315.
13. Babalik E., Gulbaran M., Gurmen T., Ozturk S. Fracture of popliteal artery stents. Circ J 2003, 67(7):643-645.
14. Sharma S., Kukreja N., Christopoulos C., Gorog D.A. Drug-eluting balloon: new tool in the box. Expert Rev Med Devices 2010, 7(3):381-388.
15. Waksman R., Pakala R. Drug-eluting balloon: the comeback kid?. Circ: Cardiovasc Interv 2009, 2(4):352-358.
16. Novack V., Cutlip D., Kleiman N., Pencina M., Mauri L., Yen C.-H., et al. In-hospital and 1-Year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (evaluation of drug eluting stents and ischemic events) registry. J Am Coll Cardiol Intv 2009, 2(8):767-775.
17. Byrne R.A., Sarafoff N., Kastrati A., Schomig A. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf 2009, 32(9):749-770.
18. Nakazawa G., Finn A.V., Kolodgie F.D., Virmani R. A review of current devices and a look at new technology: drug-eluting stents. Expert Rev Med Devices 2009, 6(1):33-42.
19. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Sophia V., Morger C., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369(9562):667-678.
20. Grines C.L., Bonow R.O., Casey D.E., Gardner T.J., Lockhart P.B., Moliterno D.J., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents - a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007, 115(6):813-818.
21. Bell B., Walters D., Spaulding C. Deciphering dual antiplatelet therapy in the era of drug-eluting coronary stents. Curr Drug Targets 2009, 10(6):519-529.
22. Berger P.B., Bhatt D.L., Fuster V., Steg P.G., Fox K.A.A., Shao M., et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Circulation 2010, 121(23):2575-2583.
23. Danenberg H.D., Fishbein I., Gao J.C., Monkkonen J., Reich R., Gati I., et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002, 106(5):599-605.
24. Epstein H., Grad E., Golomb M., Koroukhov N., Edelman E.R., Golomb G., et al. Innate immunity has a dual effect on vascular healing: suppression and aggravation of neointimal formation and remodeling post-endotoxin challenge. Atherosclerosis 2008, 199(1):41-46.
25. Wang K., Zhou X., Zhou Z., Mal N., Fan L., Zhang M., et al. Platelet, not endothelial, p-selectin is required for neointimal formation after vascular injury. Arterioscler Thromb Vasc Biol 2005, 25(8):1584-1589.
26. Paderi J.E., Panitch A. Design of a synthetic collagen-binding peptidoglycan that modulates collagen fibrillogenesis. Biomacromolecules 2008, 9(9):2562-2566.
27. Paderi J.E., Sistiabudi R., Ivanisevic A., Panitch A. Collagen-binding peptidoglycans: a biomimetic approach to modulate collagen fibrillogenesis for tissue engineering applications. Tissue Eng Part A 2009, 15:2991-2999.
28. Chiang T.M. A synthetic nonapeptide derived from the sequence of a platelet type I collagen receptor inhibits type 1 collagen-mediated platelet aggregation. Am J Med Sci 2000, 320(6):362-367.
29. Chiang T.M., Kang A.H. A synthetic peptide derived from the sequence of a type I collagen receptor inhibits type collagen-mediated platelet aggregation. J Clin Invest 1997, 100(8):2079-2084.
30. Newman P.M., Chong B.H. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000, 96(1):182-187.
31. Badimon L., Badimon J.J., Turitto V.T., Vallabhajosula S., Fuster V. Platelet thrombus formation on collagen type I - a model of deep vessel injury - influence of blood rheology, von Willebrand Factor, and blood-coagulation. Circulation 1988, 78(6):1431-1442.
32. Edwards J.M., Neeb Z.P., Alloosh M.A., Long X., Bratz I.N., Peller C.R., et al. Exercise training decreases store-operated Ca2+ entry associated with metabolic syndrome and coronary atherosclerosis. Cardiovasc Res 2010, 85(3):631-640.
33. Long X., Bratz I.N., Alloosh M., Edwards J.M., Sturek M. Short-term exercise training prevents micro-and macro-vascular disease following coronary stenting. J Appl Physiol 2009, 108(6):1766-1774.
34. Sturek M.A.M., Wenzel J., Byrd J.P., Edwards J.M., Lloyd P.G., Tune J.D., et al. Ossabaw Island miniature swine: cardiometabolic syndrome assessment. Swine in the laboratory: surgery, anesthesia, imaging, and experimental techniques 2007, 397-402. CRC Press, Boca Raton. M.M. Swindle (Ed.).
35. Lam J.Y.T., Chesebro J.H., Steele P.M., Badimon L., Fuster V. Is vasospasm related to platelet deposition - relationship in a porcine preparation of arterial injury in vivo. Circulation 1987, 75(1):243-248.
36. Surin W.R., Barthwal M.K., Dikshit M. Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis. Thromb Res 2008, 122(6):786-803.
37. Savage B., Saldivar E., Ruggeri Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996, 84(2):289-297.
38. Penc S.F., Pomahac B., Winkler T., Dorschner R.A., Eriksson E., Herndon M., et al. Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function. J Biol Chem 1998, 273(43):28116-28121.
39. Trowbridge J.M., Rudisill J.A., Ron D., Gallo R.L. Dermatan sulfate binds and potentiates activity of keratinocyte growth factor (FGF-7)*. J Biol Chem 2002, 277(45):42815-42820.
40. Gospodarowicz D., Moran J.S., Braun D.L. Control of proliferation of bovine vascular endothelial cells. J Cell Physiol 1977, 91(3):377-385.
41. Lamalice L., Le Boeuf F., Huot J. Endothelial cell migration during angiogenesis. Circ Res 2007, 100(6):782-794.
42. Saraf S.O.P., Gorog D. ClearWay Rx - Rapid exchange therapeutic perfusion catheter. EuroIntervention 2008, 3:639-642.
43. Vanhoutte P.M. Endothelial dysfunction - the first step toward coronary arteriosclerosis. Circ J 2009, 73(4):595-601.
44. Davies M.J. The composition of coronary-artery plaques. N Engl J Med 1997, 336(18):1312-1314.